Diagnostics company Thyrocare Technologies, which hit capital markets with its IPO on Wednesday, has raised Rs 144 crore through issue of shares to 15 anchor investors.
Thyrocare has allocated 32,23,411 shares to 15 anchor investors at Rs 446 per share, the upper end of the price band, aggregating Rs 143.76 crore, the company said in a statement.
The anchor investors include Nomura, Merrill Lynch Capital Markets Espana, DSP Blackrock, HDFC MF, Birla Sunlife MF, Reliance Capital, SBI MF, ICICI Prudential, Tata AIA Life Insurance, Copthall Mauritius, Spring Healthcare India Trust, FIL Investments Mauritius, L&T MF, Sundaram MF & DB International Asia.
Thyrocare plans to raise about Rs 480 crore through an initial public offering (IPO).
The company’s IPO is scheduled to close on April 29.
The firm, which runs a diagnostics laboratory chain across the country, has come out with the public issue of up to 10,744,708 shares of Rs 10 each for cash.
These shares will be sold by the company’s existing shareholders, including A Velumani HUF, Anand Velumani, Sundararaju HUF and Agalia Private.
It has fixed a price band of Rs 420 to Rs 446 for the issue. The company will garner around Rs 479.21 crore at the upper end of the price band.
Thyrocare competes with diagnostics chains such as Dr Lal PathLabs, SRL Diagnostics, Metropolis Healthcare and Apollo Clinic. It is developing a network of molecular imaging centers for cancer diagnosis.
The shares are proposed to be listed on NSE and BSE.
The issue is being managed by JM Financial Institutional Securities, Edelweiss Financial Services and ICICI Securities.
Several healthcare firms like Alkem Laboratories, Dr Lal PathLabs and Narayana Hrudayalaya came out with their IPOs last year while HealthCare Global Enterprises got listed on the stock exchanges last month.